Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 4, 73
- https://doi.org/10.3389/fendo.2013.00073
Abstract
Diabetes mellitus (DM) and osteoporosis (OP) are common disorders with a significant health burden, and an increase in fracture risk has been described both in type 1 (T1DM) and in type 2 (T2DM) diabetes. The pathogenic mechanisms of impaired skeletal strength in diabetes remain to be clarified in details and they are only in part reflected by a variation in bone mineral density. In T2DM, the occurrence of low bone turnover together with a decreased osteoblast activity and compromised bone quality has been shown. Of note, some antidiabetic drugs (e.g., thiazolidinediones, insulin) may deeply affect bone metabolism. In addition, the recently introduced class of incretin-based drugs (i.e., GLP-1 receptor agonists and DPP-4 inhibitors) is expected to exert potentially beneficial effects on bone health, possibly due to a bone anabolic activity of GLP-1, that can be either direct or indirect through the involvement of thyroid C cells. Here we will review the established as well as the putative effects of incretin hormones and of incretin-based drugs on bone metabolism, both in preclinical models and in man, taking into account that such therapeutic strategy may be effective not only to achieve a good glycemic control, but also to improve bone health in diabetic patients.Keywords
This publication has 112 references indexed in Scilit:
- A local glucagon-like peptide 1 (GLP-1) system in human pancreatic isletsDiabetologia, 2012
- Trabecular bone histomorphometry in humans with Type 1 Diabetes MellitusBone, 2012
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialThe Lancet, 2010
- Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cellsJournal of Neurochemistry, 2010
- Sclerostin: Current Knowledge and Future PerspectivesCalcified Tissue International, 2010
- Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabetic Medicine, 2008
- Taste Cells of the Gut and Gastrointestinal ChemosensationMolecular Interventions, 2008
- Relationships between fat and boneOsteoporosis International, 2007
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007
- Gastrointestinal hormones regulating appetitePhilosophical Transactions Of The Royal Society B-Biological Sciences, 2006